Based on the latest data from August 2025, AbbVie (ABBV) is trading at $210.40, positioning the stock in the **overvalued zone** between the 81.3x and 98.9x PE multiples. Specifically, the current price of $210.40 sits above the 81.3x PE boundary at $172.99 but below the 98.9x PE boundary at $210.40, indicating the stock is trading at elevated valuation levels that warrant caution. This represents a significant premium to the company's historical valuation ranges and suggests limited upside potential at current levels. Analyzing the historical trend reveals a dramatic valuation expansion story for AbbVie over the past five years. The stock began 2020 trading in the **undervalued zone** below the 11.0x PE multiple at around $68.86, representing an attractive entry point. Throughout 2020-2021, ABBV gradually moved through the **value** and **fair value zones**, reaching the **watch zone** between 46.1x-63.7x PE multiples by late 2021 at approximately $111. The most significant valuation expansion occurred from 2022 onwards, with the stock consistently trading in the **overvalued** and **warning zones**. Notable peaks include March 2025 at $206.45 and the current August 2025 level of $210.40, both representing the highest valuations in the analyzed period. This sustained elevation above the 63.7x PE multiple since 2022 indicates that AbbVie has experienced substantial multiple expansion, moving from historically attractive valuations to premium territory that suggests investors should exercise heightened caution when considering new positions.